Please login to the form below

Not currently logged in
Email:
Password:

bimagrumab

This page shows the latest bimagrumab news and features for those working in and with pharma, biotech and healthcare.

Pfizer abandons antibody for Duchenne

Pfizer abandons antibody for Duchenne

Novartis and Morphosys gave up on their bimagrumab for muscle-wasting disease sporadic inclusion body myositis two years ago, while Shire/Acceleron and Amgen have also chalked up failures in this

Latest news

  • Novartis orphan drug wins 'breakthrough' status from FDA Novartis orphan drug wins 'breakthrough' status from FDA

    Novartis orphan drug wins 'breakthrough' status from FDA. Bimagrumab could be first treatment for rare life-threatening muscle-wasting condition. ... With no effective therapies currently available for sIBM, bimagrumab has the potential to be the first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics